Haemodynamic Effects of Enalapril, a New Converting Enzyme Inhibitor, in Hypertensive Patients

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1985 Jan 1

PMID 2996905

Citations 1

Authors

M Velasco

H Silva

J Morillo

R Pellicer

A Ramirez

A Urbina

H J Gomez

Affiliations

Soon will be listed here.

Abstract

The haemodynamic effects of enalapril (EN), a new, long-acting, nonsulphhydryl converting enzyme inhibitor, were evaluated by non-invasive methods in 10 adult patients with mild to moderate essential hypertension (EH). Patients were randomly assigned, double blind to 2 treatment groups (EN 20 mg o.d. or 10 mg b.d.) for 4 weeks, and were crossed over to the other dosage regimen after a 2-week washout period. Measurements included mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), limb blood flow (LBF), plasma aldosterone (ALD), plasma renin activity (PRA) and systolic time intervals (STI). Both regimens (b.d. and o.d.) significantly reduced MAP (15.3% and 16.3%, respectively), total peripheral resistance (20.3% and 21.8%, respectively), limb vascular resistance (24.1% and 24.9%) and ALD (33.5% and 36.9%) and increased CO (7.8% and 8.7%), LBF (10.9% and 11.6%) and PRA (10.4% and 9.5%). No significant change was observed in HR or STI. EN 20 mg o.d. or 10 mg b.d. reduced arterial pressure to a similar extent through a fall in total peripheral resistance. An increase in CO was also observed.

Citing Articles

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Todd P, Heel R Drugs. 1986; 31(3):198-248.

PMID: 3011386 DOI: 10.2165/00003495-198631030-00002.

References

Ibsen H, Egan B, Osterziel K, Vander A, Julius S . Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension. 1983; 5(2 Pt 2):I184-91. DOI: 10.1161/01.hyp.5.2_pt_2.i184. View

Haber E, Koerner T, PAGE L, KLIMAN B, Purnode A . Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969; 29(10):1349-55. DOI: 10.1210/jcem-29-10-1349. View

WEISSLER A, Garrard Jr C . Systolic time intervals in cardiac disease. I. Mod Concepts Cardiovasc Dis. 1971; 40(1):1-4. View

Hodsman G, Brown J, Davies D, Fraser R, Lever A, Morton J . Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis. Br Med J (Clin Res Ed). 1982; 285(6356):1697-9. PMC: 1500652. DOI: 10.1136/bmj.285.6356.1697. View

Greenfield A, WHITNEY R, Mowbray J . Methods for the investigation of peripheral blood flow. Br Med Bull. 1963; 19:101-9. DOI: 10.1093/oxfordjournals.bmb.a070026. View

Fraser R, Guest S, Young J . A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973; 45(3):411-5. DOI: 10.1042/cs0450411. View

Hodsman G, Brown J, Cumming A, Davies D, East B, Lever A . Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. J Hypertens Suppl. 1983; 1(1):109-17. View

PATCHETT A, Harris E, Tristram E, Wyvratt M, Wu M, Taub D . A new class of angiotensin-converting enzyme inhibitors. Nature. 1980; 288(5788):280-3. DOI: 10.1038/288280a0. View

Bravo E, TARAZI R . Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979; 1(1):39-46. DOI: 10.1161/01.hyp.1.1.39. View

10.

Gross D, Sweet C, Ulm E, Backlund E, MORRIS A, Weitz D . Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther. 1981; 216(3):552-7. View

11.

DiNicolantonio R, HUTCHINSON J, Mendelsohn F, Doyle A . In vivo comparison of three orally active inhibitors of angiotensin-converting enzyme. Am J Cardiol. 1982; 49(6):1502-4. DOI: 10.1016/0002-9149(82)90368-x. View

12.

Sweet C, Gross D, Arbegast P, Gaul S, Britt P, LUDDEN C . Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther. 1981; 216(3):558-66. View

13.

Morganti J, Pickering T, LARAGH J . Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion. J Clin Endocrinol Metab. 1980; 50(4):748-54. DOI: 10.1210/jcem-50-4-748. View

14.

Biollaz J, Burnier M, Turini G, Brunner D, Porchet M, Gomez H . Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981; 29(5):665-70. DOI: 10.1038/clpt.1981.92. View

15.

Antonaccio M, McGill M . Comparative effects of captopril and MK 421 on sympathetic function in spontaneously hypertensive rats. Am J Cardiol. 1982; 49(6):1533-4. DOI: 10.1016/0002-9149(82)90379-4. View

16.

Clough D, Conway J, Hatton R, Scott K . The effect of angiotensin converting enzyme inhibitor on baroreceptor reflexes in conscious dogs during sodium depletion [proceedings]. J Physiol. 1979; 295:75P-76P. View

17.

Gavras H, Brunner H, Turini G, KERSHAW G, Tifft C, Cuttelod S . Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978; 298(18):991-5. DOI: 10.1056/NEJM197805042981803. View

18.

KUBICEK W, KARNEGIS J, Patterson R, Witsoe D, Mattson R . Development and evaluation of an impedance cardiac output system. Aerosp Med. 1966; 37(12):1208-12. View

19.

Atkinson A, Robertson J . Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979; 2(8147):836-9. DOI: 10.1016/s0140-6736(79)92186-x. View

20.

Lababidi Z, EHMKE D, Durnin R, Leaverton P, Lauer R . Evaluation of impedance cardiac output in children. Pediatrics. 1971; 47(5):870-9. View